Back to top

Analyst Blog

Nektar Therapeutics (NKTR - Analyst Report) reported a loss of 37 cents per share in the second quarter of 2013, wider than the year-ago loss of 30 cents but narrower than the Zacks Consensus Estimate of a loss of 44 cents. The wider year-over-year loss during the quarter was primarily due to higher expenses.

However, Nektar’s share price was up significantly following the second quarter 2013 results based on strong top-line results.

Quarter in Details

Total revenues in the reported quarter jumped 43% to $33.9 million. The increase in quarterly revenues was primarily due to a $10.0 million milestone received from Bayer (BAYRY - Analyst Report) for the initiation of phase III studies on Amikacin Inhale. Second quarter revenues were also benefited from higher product sales. Revenues were well above the Zacks Consensus Estimate of $24 million.

Amikacin Inhale is being developed for the treatment of gram-negative bacterial pneumonias in ventilated patients. Results from phase III studies are expected by the first half of 2015.

Total revenues comprised net product revenues, royalty revenues, non-cash royalty revenues, license and collaboration revenues and others.

Nektar’s net product revenues of approximately $10.3 million were up 6.5% during the reported quarter.

Nektar’s royalty revenues decreased 21% to $0.4 million during the quarter. The company’s license, collaboration and other revenues however increased 89.2% to $19.4 million in the reported quarter primarily due to the milestone received from Bayer.

Research and development (R&D) expenses were up 57.3% to $52.2 million in the second quarter of 2013. R&D expenses during the quarter increased primarily due to higher clinical expenses related to its pipeline.

The company recently completed the enrolment process for the phase III BEACON study on its metastatic breast cancer candidate NKTR-102 (etirinotecan pegol). Nektar Therapeutics plans to conduct an interim futility analysis on the phase III study at the beginning of 2014 and expects top-line survival data by the end of that year.

Nektar’s general and administrative (G&A) expenses decreased 10.1% to $9.2 million during the quarter.

2013 Outlook

Apart from disclosing its financial results, Nektar maintained its guidance for 2013. The company still expects total revenues in the range of $200–$210 million, including potential milestone payments of $95 million. The revenue guidance also includes $20 million of non-cash royalty revenues in relation to Cimzia and Mircera.

Nektar also reiterated its R&D expenses for 2013 in the range of $200 million to $220 million. Nektar’s G&A expenses for 2013 are also maintained in the range of $42–$44 million.

Our Take

The company’s second-quarter 2013 results were encouraging. We are also impressed with the pipeline progress at Nektar. We expect investor focus to stay on the company’s pipeline going forward.

Nektar, a biopharma company, currently carries a Zacks Rank #3 (Hold). However, among other biopharma stocks, Actelion Ltd. (ALIOF) and Biogen Idec Inc. (BIIB - Analyst Report) currently looks better positioned with a Zacks Rank #1 (Strong Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 27.00 +10.25%
CANADIAN SO… CSIQ 38.34 +8.18%
BANCO DO BR… BDORY 16.78 +8.05%
CENTURY ALU… CENX 26.97 +7.97%
WILLDAN GRO… WLDN 11.38 +5.86%